Related Experiment Videos

Antithrombotic therapy in unstable angina/non-ST elevation myocardial infarction: the evolving role of

E M Antman1, D J Kereiakes

  • 1Cardiovascular Division, Brigham and Women s Hospital, 75 Francis Street, Boston, MA, 02115, USA.

The Journal of Invasive Cardiology
|January 13, 2001
PubMed

Insights

Low-molecular-weight heparins (LMWH) offer a superior alternative to unfractionated heparin (UFH) for managing acute coronary syndromes (ACS). Enoxaparin, an LMWH, demonstrated better outcomes than UFH in major trials for ACS treatment.

Area of Science:

  • Cardiology
  • Pharmacology
  • Thrombosis

Background:

  • Acute coronary syndromes (ACS) arise from myocardial blood flow disturbances due to thrombotic vessel occlusion.
  • Effective antithrombotic therapy is vital for managing ACS progression.
  • Unfractionated heparin (UFH) is a conventional treatment but has limitations.

Purpose of the Study:

  • To evaluate the efficacy of low-molecular-weight heparins (LMWH) as an alternative antithrombotic therapy in ACS.
  • To compare LMWH, specifically enoxaparin, with UFH in ACS management.

Main Methods:

  • Review of clinical data and outcomes from large randomized trials comparing enoxaparin with UFH.
  • Analysis of antithrombotic efficacy and safety profiles.

Main Results:

  • Enoxaparin demonstrated superiority over UFH in two large randomized trials for ACS treatment.
  • LMWH offers a convenient and effective alternative to UFH, addressing some of its limitations.

Conclusions:

  • Low-molecular-weight heparins (LMWH) represent a significant therapeutic advancement in the management of ACS.
  • Further research will refine the optimal role of LMWH in ACS treatment protocols.

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...